Pharma & Biotech’s Merger Fever: The Highlights
Add bookmark
In 2015, the pharma and biotech industry was diagnosed with what was coined as merger fever. Industry analysts state that the first half of 2015 soared past 2014’s grand total of $162 billion, with the total value of pharma M&As in the first two quarters of 2015 sitting at $221 billion.[13]Cheap interest rates fuelled the M&A buzz, with acquisitions providing pharma firms with the growth to match investor expectations. This growth is reflected in share prices, earnings as well as portfol...
